Simple jQuery Dropdowns

Browsing by Author Ricardo Pasquini

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)
15-Sep-2009Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian; Ricardo Pasquini; Vincent Lévy; Saengsuree Jootar; Jerzy Holowiecki; Nelson Hamerschlak; Timothy Hughes; Eric Bleickardt; David Dejardin; Jorge Cortes; Neil P. Shah; University of Texas MD Anderson Cancer Center; Hospital de Clínicas de Curitiba; Hopital Saint-Louis; Mahidol University; University Hospital-SPSKM; Hospital Israelita Albert Einstein; Institute of Medical and Veterinary Science Australia; Bristol-Myers Squibb; UCSF School of Medicine
17-Jun-2010Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio; Dong Wook Kim; Surapol Issaragrisil; Philipp Le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E. Clark; Andreas Hochhaus; Timothy P. Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A. Larson; Hagop M. Kantarjian; Universita degli Studi di Torino; The Catholic University of Korea; Mahidol University; Charité – Universitätsmedizin Berlin; Institut Bergonie; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti; Universidade Federal do Parana; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Universitatsklinikum Jena und Medizinische Fakultat; Royal Adelaide Hospital; Novartis International AG; Novartis Pharmaceuticals; University of Chicago; University of Texas MD Anderson Cancer Center